Meloxicam Flamingo

Meloxicam, the active ingredient in Meloxicam Flamingo, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral dosage form for oral use. It reduces inflammation and pain in musculoskeletal conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and in acute pain episodes.

GNH USA supplies Meloxicam Flamingo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across EU and other markets.

Meloxicam is indicated for several inflammatory and pain‑related conditions affecting the musculoskeletal system.

Osteoarthritis: reduces joint pain and improves mobility in patients with degenerative joint disease. Rheumatoid arthritis: alleviates inflammation and pain in chronic autoimmune joint inflammation. Ankylosing spondylitis: decreases spinal stiffness and discomfort associated with the disease. Acute pain: provides short‑term relief of moderate to severe pain from various causes.

Meloxicam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia - Headache or dizziness - Peripheral edema or mild hypertension - Skin rash or pruritus - Elevated liver enzymes - Mild renal function changes

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Severe liver injury (hepatitis, jaundice) - Acute renal impairment or failure - Cardiovascular thrombotic events (myocardial infarction, stroke) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylaxis or severe hypersensitivity reactions

When prescribing meloxicam, clinicians should consider several safety aspects.

Renal function: assess baseline kidney function and monitor during therapy, especially in patients with pre‑existing renal disease. Cardiovascular risk: use cautiously in patients with hypertension, heart failure or a history of thrombotic events. Gastrointestinal safety: consider gastroprotective agents for patients with prior ulcer disease. Pregnancy and lactation: category B; avoid use unless benefits outweigh risks. Concomitant NSAIDs or anticoagulants: increase risk of bleeding; avoid combination when possible. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Meloxicam can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Selective COX‑2 inhibitors (e.g., celecoxib): additive toxicity. - Methotrexate: reduced clearance leading to toxicity. - Lithium: increased serum levels. - Cyclosporine: heightened nephrotoxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: enhanced risk of renal impairment and electrolyte imbalance. - SSRIs or SNRIs: elevated bleeding tendency. - Beta‑blockers: may mask tachycardia from NSAID‑induced fluid retention. - Allopurinol: potential for hypersensitivity reactions.